Studies were completed in F344/N rats and B6C3F, mice to determine the effect of dose, dose rate, route of administration, and rodent species on formation of total and individual benzene metabolites. Oral doses of 50 mg/kg or higher saturated the capacity for benzene metabolism in both rats and mice, resulting in an increased proportion of the administered dose being exhaled as benzene. The saturating air concentration for benzene metabolism during 6-hr exposures was between 130 and 900 ppm. At the highest exposure concentration, rats exhaled approximately half of the internal dose retained at the end of the 6-hr exposure as benzene; mice exhaled only 15% as benzene. Mice were able to convert more of the inhaled benzene to metabolites than were rats. In addition, mice metabolized more of the benzene by pathways leading to the putative toxic metabolites, benzoquinone and muconaldehyde, than did rats. In both rats and mice, the effect of increasing dose, administered orally or by inhalation, was to increase the proportion of the total metabolites that were the products of detoxification pathways relative to the products of pathways leading to putative toxic metabolites. This indicates low-affinity, high-capacity pathways for detoxification and high-affinity, low-capacity pathways leading to putative toxic metabolites. If the results of rodent studies performed at high doses were used to assess the health risk at low-dose exposures to benzene, the toxicity of benzene would be underestimated.
Introduction Problem
In the absence of dose-response data in humans, longterm rodent studies involving hundreds of animals are used to predict the carcinogenicity of compounds for people. However, the responses of rodents to compounds may vary widely between species, both in the type of response and in the amount of compound eliciting a response. Also, for convenience or for economic reasons, rodent studies may not use the same route of exposure or the same dose rate as that expected in humans. To be able to interpret these animal data for extrapolation to Inistitute, P.O. Box 5890, Albuquerque, NM 87185. health risk assessments for humans, one must obtain more information on the basis for the rodent responses. Important areas to consider are the effect of species, route of exposure, and dosing regimen on the disposition and metabolic fate of the administered material. Such information is critical for determining the biologically effective dose delivered to target sites in the body under the different exposure situations. The following is a report of studies conducted at the Lovelace Inhalation Toxicology Research Institute in collaboration with the National Institute of Environmental Health Sciences to determine the disposition and metabolic fate of benzene in rats and mice under different exposure conditions.
Background
The major concern in chronic exposures of humans to benzene is its adverse hemopoietic effects and neoplastic or preneoplastic effects in other tissues. The incidence of leukemia, pancytopenia, and preleukemia in humans exposed to benzene is significantly higher than in the gener al population (1) . Benzene may also be a factoi in the development of other forms of cancer, such as Hodgkin's disease, multiple myeloma, and lung cancer (1) .
Studies by Maltoni et al. (2, 3) and by the National Toxicology Program (NTP) (4) clearly show that benzene administereed to rodents by gavage or inhalation pr oduces ineoplasia in a variety of tissues. In the NTP studies B6C3F i mice and female F344/N rats received 0, 25, 50, 100 mg benzene/kg orally, in corn oil, 5 days/week for 103 weeks. Male F344/N riats received 0, 50, 100, and 200 mg benzene/kg in the same dosing regimen. Maltoni and coworkers exposed Sprague-Dawley riats to 200 to 300 ppm benzene during a 2-year period and also conducted an oral stu(ly in which Sprague-Dawley rats were administer ed 0, 50, and 250 mg benzene/kg in olive oil, 5 times/week for 52 weeks and were held for 92 weeks for observation. The tumorigenic riesponses in these studies were species-(lependlent. Mice developed neoplasms in the lung, Harderian gland, preputial gland, ovary, mammary gland, aind liver while rats did not. Benzene induced neoplasms in the Zymbal gland of both riats and mice and in the oral cavity and skin of rats only. To interpret the riesults of such animal studies for human risk assessment, it is important to know the effect of species, rioute of administratioin, total inteinal dose, and rate at which the dose was delivered on the disposition and metabolic fate of the benzene.
Approach
Two types of studies were conducted to address the problem (lescribed. First, '4C-benzene was used to determinie the effect of species, exposure dose, and route of exposure on the excretion patterns and total metabolites formedl from benzene. ("Exposure dose" is used here to in(licate the amount of material presented to the animal by ainy rioute of exposure, i.e., the amount orally instilled, the amount injected, IP, or the inhalation exposure concentration over a specific time.) Second, the effect of species, exposure dose, exposure dose rate, and the route of exposure on tissue and blood levels of individual metabolites was determined using 3H-benzene. The 3H-benzene was riequired to obtain a high enough specific activity in benzene metabolites to be able to detect them in tissues. Because the individual metabolites were isolated prior to rcadioactivity determination, there was not a problem with measuring tritium that was not associated with the metabolites. Initial studies using both 14C-and 3H-labeled benzene indicated only a minor (X\10%) isotope effect for a ny of the metabolites (7).
Methods
The methods for the conduct of the studies have been published (5) (6) (7) (8) . Inhalation exposures were in nose-only chambers described by Raabe et al. (9) . Analysis of organic-soluble metabolites of benzene (7) (5) . '4C-Benzene was administered to the species used in the long-term bioassay studies (F344/N rats, Sprague-Dawley rats, and B6C3F1 mice) orally, by IP injection, and by inhalation. In the inhalation studies, the internal dose retained in the animals was determined at the end of the 6-hr exposure by liquid scintillation spectroscopy. Routes of excretion were determined by measuring 14C in urine, feces, and exhaled air (separating CO2 from benzene) for 48 hr after dose administration. Total metabolites were determined by summing the 14C-activity in urine, feces, C02, and remaining in the carcass. Mass balance between the administered dose and the total amount excreted or retained in the body was determined and indicated recoveries of 100 + 12% (x + SD, n = 19 studies) (5) .
By any route of exposure, over 95% of the administered radioactivity had been excreted in 48 hr, and approximately 90% of all metabolites were excreted in the urine. In both rats and mice, there was an increased amount of the aclmiinistered dose that was exhaledl as benzene at (loses of 50 mg/kg or higher (Fig. 1) . [There were no differences in the riesults observedl in the two strains of rats (5); therefore, the rat data have been combined.] The same excretion patterns were observed after IP injection (Fig. 2) . Concomitant with the increased amount of exhaled benzene at the higher doses, there was a decrease in the percent of the dose converted to metabolites.
The results from the inhalation study are shown in Ta (Table 2) , one finds that it is difflcult to achieve as high a level of benzene metabolites in a mouse by a single oral dose as one can achieve by inhalation. In summary, this study indicated a) benzene is rapidly metabolized and excreted, mainly as water-soluble metabolites in urine, within 40 hr of dosing by any route; b) bolus doses of 50 mg/kg or higher exceed the ability of rodents to metabolize benzene and part of the dose will be lost by exhalation of benzene; c) mice metabolize benzene more rapidly than rats; and d) benzene administered at a slow dose rate, as in an extended (e.g., 6 hr) inhalation exposure, will result in higher internal doses in mice than bolus dosing. According to these data, almost all the oral doses given in the long-term bioassay studies described in the background section of this paper were beyond the linear range for formation of metabolites in the rodents. Because the high doses are not converted to metabolites as efficiently as lower doses, the use of the (Fig. 1); experimentally, we did not achieve total metabolite levels higher than 50 mg/kg in mice by a single oral dose. According to a mathematical model based on these data, a single oral dose of greater than 300 mg/kg wvould be required to achieve 80 mg/kg benzene metabolites in mice.
bioassay data to predict the effects of low doses of benzene may underestimate the toxicity of the compound.
Benzene Metabolites
The next part of our study was to determine the effect of species and dosing regimen on the amount of individual benzene metabolites in blood and tissues because our information on total metabolites formed did not distinguish between toxic and nontoxic metabolites. The major metabolic pathways of benzene (4) are illustrated in Figure 3 . There are several detoxification pathways. One is the formation of glutathione conjugates of benzene oxide leading to formation of prephenyl mercapturic and phenyl mercapturic acid. A second is the formation of glucuronide or sulfate conjugates of phenol. Two metabolic pathways form putative toxic metabolites, muconaldehyde (10) and benzoquinone (11) . In our analyses, we have used stable compounds at the end or close to the end of these pathways as markers for the amount of the benzene being metabolized by the different pathways (Table 3 ). In all blood or tissue samples analyzed, greater than 90% of metabolites were in water-soluble forms (Table 4) . Therefore, major emphasis was placed on quantitating the water-soluble benzene metabolites as indicative of benzene metabolism through the major pathways.
Species Differences in Benzene Metabolism
This study has been reported in detail previously (6) . F344/N rats and B6C3F1 mice were exposed by inhalation to 50 ppm 3H-benzene for 6 hr. Tissue and blood samples were analyzed for benzene and its metabolites both during and for 8 hr after the exposure and the metabolite concentration plotted versus time. The integrated dose to a tissue over the 14-hr period (6 hr of exposure, 8 hr following exposure) was calculated for each metabolite (area under curve or AUC). The results are shown in Table 4 .
The major metabolic products in rats were detoxification products-phenyl conjugates. Hydroquinone and its conjugates, hydroquinone glucuronide and hydroquinone sulfate, were either not detectable in rats or present in trace quantities. On the other hand, mice had substantial quantities of the markers for the toxification pathways (muconic acid, hydroquinone glucuronide, and hydroquinone sulfate) in tissues in addition to the markers for the detoxification pathways. Bone marrow samples taken at different times were pooled to have sufficient radioactivity for analysis (Fig. 4) . The only metabolite detected in rat bone marrow was phenyl sulfate. In mouse bone marrow, muconic acid and hydroquinone glucuronide were also detected. Thus, not only do mice metabolize benzene faster than rats, mice also form more of the putative toxic metabolites than do rats. This study has been reported in detail elsewhere (12) . F344/N rats and B6C3F1 mice were exposed orally to 1, 10, and 200 mg 3H-benzene/kg body weight or by inhalation to 5, 50, or 600 ppm 3H-benzene for 6 hr. The highest oral dose and exposure concentration were expected to be outside the linear range for total metabolism of benzene as determined by earlier studies. ("Linear range" refers to a linear relationship between exposure dose and (7) and Sabourin et al. (8) . . Water-soluble benzene metabolites in samples taken during and for 8 hr following a 6-] os!ll p n{f\nno 0m3y"r c! no+net-el"or at K)r OS benzene (Fig. 5 ) was linear with respect to exposure dose ll s.o 1 ' =zzat 600 ppm in mice but not in rats. (In mice, the curve was shifted to the right in the 600-ppm exposure, but the l+ AUC/ppm was not different from that of the two lower z exposure concentrations.) In contrast, the amount of muconic acid formed was nonlinear after all inhalation exposure concentrations in both species, with proportionally (as percent of the exposure concentration) more muconic acid formed at the lower exposure concentration. If muconic acid is involved in the toxicity from inhaled benzene, one would underestimate the toxicity of the compound if one extrapolated from the effects at high doses in animal studies to expected results at low doses.
METABOLIC SCHEME FOR BENZENE
Following oral exposures of rats, the blood concentra-30 40
tions of both phenyl sulfate and muconic acid were nonlinearly related to dose at the highest exposure dose, indicating saturation of both pathways of metabolism. In mice there was a saturation of the pathway leading to muconic acid formation but a trend toward increased forma-. Sad) tion of the detoxification metabolite, phenyl sulfate.
In addition, an increasing proportion of the inhaled bento zene was converted to glutathione conjugates and to phenyl glucuronide at the higher exposure concentration LU in mice (12) . Thus, in mice, there appeared to be a shift toward detoxification pathways at the higher exposure . J + dose. Hydroquinone conjugates were barely detectable z in rats but decreased in proportion relative to the exposure concentration in mice in a manner similar to that observed for muconic acid. The same trends toward increased formation of glutathione conjugates and phenyl glucuronide and decreased formation of hydroquinone conjugates at the highest dose were noted in orally exposed mice.
30
40 In summary, the effect of increasing dose, administered to rats or mice either orally or by inhalation, was to increase the proportion of markers of detoxification pathpooled bone marrow ways relative to the markers of pathways leading to putahr 50-ppm 3H-benzene tive toxic metabolites.
exposure Woi. D1one marrow samnpies LKen aTl vanous ulme pOmlIlS were pooled and processed and analyzed by HPLC as described in "Methods." The HPLC chromatogram is shown. Numbers above each peak refer to the nmole metabolite per gram of bone marrow tissue. The internal standard was p-nitrophenyl glucuronide (PNPG).
the amount of total benzene metabolites formed.) It was not known if these exposure levels would be outside the linear range for the amount of individual metabolites formed. The amount of individual benzene metabolites formed per unit of exposure was determined in blood and major tissues. Representative results for a marker of the major detoxification pathway (phenyl sulfate) and a marker of a toxification pathway (muconic acid) in the blood are illustrated in Figure 5 for inhaled benzene and in Figure 6 for orally administered benzene. Because previous studies indicated differences between a bolus dose (given orally) and a dose administered over 6 hr (by inhalation) (5), a study was designed to determine the effect on benzene metabolism of extended inhalation exposures to low concentrations versus short exposures to high levels (12) . Fischer 344/N rats and B6C3F1 mice were exposed by inhalation to one of three exposure regimens, all having the same concentration x time factor: 600 ppm benzene for 0.5 hr, 150 ppm for 2 hr, or 50 ppm for 6 hr. The AUCs for benzene metabolites in blood and tissues were determined. If there were no dose rate effects, the ACUs should be the same for all exposure regimens. In general, there was no dose-rate effect in rats. In mice, however, the fast exposure rate (0.5 hr x 600 ppm) produced less muconic acid in blood, liver, and lung (Fig. 7) . In the blood and lung, less hydroquinone 
Summary
The results of these studies indicate mice metabolize benzene faster than rats and convert more of the benzene to toxic metabolites that do rats. For both species, in general, the detoxification pathways for benzene appear to be low-affinity, high-capacity pathways, whereas pathways leading to the putative toxic metabolites appear to Muconic Acid TIME FROM START OF EXPOSURE (hr) FIGURE 6 . Blood metabolites following an oral exposure of F344/N rats and B6C3FI mice to 1, 10, The major objective of these studies was to obtain information to allow better extrapolation of the results of animal studies to expected results in humans. To achieve, this, the animal data have been used to develop a mathematical model to predict the disposition and metabolic fate of benzene under all exposure conditions in rodents (13, 14) . The next step is to alter the physiological parameters used in this model to fit the known physiological values for humans. The model can also be strengthened by making use of known values for metabolism of benzene by human tissues in vitro. Finally, limited data from humans exposed accidentally to benzene can be used to validate the model. With this approach, the animal toxicokinetic data developed in these studies should prove useful in improving our ability to assess human health risks associated with benzene exposures. 
